CIK 1983313
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2024-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 90.99% | 18 |
| Unclassified | 9.01% | 3 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | BMY | BRISTOL MYERS SQUIBB CO | Health Care | 7.83% |
| 2 | AMGN | AMGEN INC | Health Care | 6.78% |
| 3 | BIIB | BIOGEN INC. | Health Care | 6.76% |
| 4 | LLY | ELI LILLY & Co | Health Care | 6.47% |
| 5 | INSM | INSMED Inc | Health Care | 6.19% |
| 6 | RARE | Ultragenyx Pharmaceutical Inc. | Health Care | 5.98% |
| 7 | BBIO | BridgeBio Pharma, Inc. | Health Care | 5.88% |
| 8 | PRGO | PERRIGO Co plc | Health Care | 5.85% |
| 9 | ROIV | Roivant Sciences Ltd. | Health Care | 5.71% |
| 10 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Health Care | 5.37% |
18/21 names classified · sector 91.0% of weight · industry 91.0% · mkt cap 91.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 91.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 42% of book weight classified — the grid is NOT representative of the whole book.
Classified: 42.4% of book weight (7/20 names) · unclassified 57.6%: , INSM, RARE, BBIO, ROIV, RPRX, TARS, MDGL, SMMT, CYTK +3 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | BMYBRISTOL-MYERS SQUIBB CO | 295,000 | $18M | 7.8% | NEW |
| 2 | AMGNAMGEN INC | 50,000 | $16M | 6.8% | ADD 31% |
| 3 | BIIBBIOGEN INC | 113,500 | $16M | 6.8% | NEW |
| 4 | LLYELI LILLY & CO | 18,000 | $15M | 6.5% | NEW |
| 5 | INSMINSMED INC | 186,384 | $14M | 6.2% | TRIM −12% |
| 6 | RAREULTRAGENYX PHARMACEUTICAL IN | 379,303 | $14M | 6.0% | TRIM −7% |
| 7 | BBIOBRIDGEBIO PHARMA INC | 390,644 | $14M | 5.9% | TRIM −30% |
| 8 | PRGOPERRIGO CO PLC | 479,517 | $13M | 5.9% | ADD 63% |
| 9 | ROIVROIVANT SCIENCES LTD | 1,300,000 | $13M | 5.7% | NEW |
| 10 | TEVATEVA PHARMACEUTICAL INDS LTD | 801,806 | $12M | 5.4% | ADD 37% |
| 11 | RPRXROYALTY PHARMA PLC | 356,894 | $11M | 4.8% | TRIM −53% |
| 12 | TARSTARSUS PHARMACEUTICALS INC | 205,000 | $11M | 4.6% | ADD 82% |
| 13 | VERONA PHARMA PLC | 160,000 | $10M | 4.4% | NEW |
| 14 | MDGLMADRIGAL PHARMACEUTICALS INC | 24,000 | $8M | 3.5% | NEW |
| 15 | SMMTSUMMIT THERAPEUTICS INC | 400,000 | $8M | 3.4% | NEW |
| 16 | HALOHALOZYME THERAPEUTICS INC | 120,000 | $8M | 3.3% | NEW |
| 17 | CYTKCYTOKINETICS INC | 175,000 | $7M | 3.1% | NEW |
| 18 | AGIOAGIOS PHARMACEUTICALS INC | 235,350 | $7M | 3.0% | TRIM −22% |
| 19 | CENTESSA PHARMACEUTICALS PLC | 418,127 | $6M | 2.6% | ADD 184% |
| 20 | RCUSARCUS BIOSCIENCES INC | 731,818 | $6M | 2.5% | NEW |
| 21 | NAMSNEWAMSTERDAM PHARMA COMPANY | 221,152 | $5M | 2.0% | TRIM −34% |
Where this firm's principals came from and which firms its alumni went on to found.
